The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
about
Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats.Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases.Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats.Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Elevated CSF N-acetylaspartylglutamate in patients with free sialic acid storage diseasesSelective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices.Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disordersCurrent approaches with the glutamatergic system as targets in the treatment of neuropathic pain.DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders.Small-molecule PSMA ligands. Current state, SAR and perspectives.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseTowards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials.Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies.Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system.
P2860
Q33641563-2D03F9BF-E488-4D36-A95A-D3C26E9D6008Q34143204-ECB0BAFE-B086-48F7-AA5E-F643DB42A491Q34256889-47D4BAEF-634D-4F3B-9902-189B466F0F3CQ34293335-2CB11B8E-EADA-47F1-B8F1-DC9DA6F8A7CBQ34345914-DA24BB22-17C9-419F-BD51-A143E5863F3BQ35065452-147911C7-4090-4E4C-B89D-805A7F562687Q35685315-D6846474-72E2-4C4F-87FA-7DB8BAB57688Q36017364-0BCFA94B-8B5A-4BAE-94C6-6BD2833A81E8Q36406289-297BCD3B-496D-4CEF-B09D-7EFA15C2E927Q36868552-79819492-E6B9-457C-94C0-B8170E80FBA5Q37523991-CB9E989A-AEF2-4F03-8654-4D0DAFE90096Q37649509-5AE9388F-80CF-48AC-80B8-B6CA68E7F928Q38185090-F1A93444-259E-41BB-95BA-48D0819DFC53Q38737674-79C3506E-17B3-4D5C-B67E-36F602E4DBA2Q38831232-AEBD372D-98F5-4977-8F0B-7DEF42A1ABA1Q39780216-BFD53B24-2A1E-456F-94C2-A67660242354Q40475257-309A6A8E-3AB2-429E-91D7-8ECEB530E84CQ41835043-27640C50-BE36-48B2-B8ED-4321689144DAQ41911926-8DB88037-7163-48C9-8699-D7A1E38382ADQ46242349-5B8F169D-0FC1-4649-939A-24C2534A30A9
P2860
The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The central nervous system eff ...... NAALADase-inhibitor GPI 5693.
@ast
The central nervous system eff ...... NAALADase-inhibitor GPI 5693.
@en
type
label
The central nervous system eff ...... NAALADase-inhibitor GPI 5693.
@ast
The central nervous system eff ...... NAALADase-inhibitor GPI 5693.
@en
prefLabel
The central nervous system eff ...... NAALADase-inhibitor GPI 5693.
@ast
The central nervous system eff ...... NAALADase-inhibitor GPI 5693.
@en
P2093
P2860
P1476
The central nervous system eff ...... e NAALADase-inhibitor GPI 5693
@en
P2093
B S Slusher
J M A van Gerven
J P van der Post
M L de Kam
M Woelfler
S J de Visser
P2860
P304
P356
10.1111/J.1365-2125.2005.02396.X
P407
P577
2005-08-01T00:00:00Z